Peptide-MHC-targeted retroviruses enable
Journal
bioRxiv : the preprint server for biology
ISSN: 2692-8205
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
22 Sep 2024
22 Sep 2024
Historique:
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
epublish
Résumé
Tumor-infiltrating-lymphocyte (TIL) therapy has demonstrated that endogenous T cells can be harnessed to initiate an effective anti-tumor response. Despite clinical promise, current TIL production protocols involve weeks-long
Identifiants
pubmed: 39345591
doi: 10.1101/2024.09.18.613594
pmc: PMC11429759
pii:
doi:
Types de publication
Journal Article
Preprint
Langues
eng